Andelen af patienter som havde post- behandling ALAT- stigninger, i forbindelse med en stigning i billirubin niveauer, var lav og ensartet hos patienter der modtog enten lamivudin eller placebo.
The proportion of patients who had post-treatment ALT elevations in association with an increase in bilirubin levels was low and similar in patients receiving either lamivudine or placebo.